| NEWLINK GENETICS CORP | |
|-----------------------|--|
| Form 8-K | |
| March 25, 2014 | |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2014 (March 25, 2014)

NewLink Genetics Corporation

(Exact name of registrant as specified in its charter)

Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

2503 South Loop Drive

Ames, IA 50010

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (515) 296-5555

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 - Other Events

Item 8.01. Other Events.

On March 25, 2014, NewLink Genetics (NASDAQ:NLNK) announced that two poster presentations highlighting its IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor programs, will be presented at the upcoming American Association of Cancer Research (AACR) meeting which will take place April 5-9, 2014 in San Diego, CA.

The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description

Press Release, dated March 25, 2014, entitled "NewLink Genetics to Present Data at the AACR

2014 Annual Meeting"

SIGNATURES

Its:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 25, 2014

NewLink Genetics Corporation

By: /s/ Gordon H. Link, Jr.

Gordon H. Link, Jr. Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number Description

Press Release, dated March 25, 2014, entitled "NewLink Genetics to Present Data at the AACR

2014 Annual Meeting"